Impax Laboratories, Inc.

Google Inc.

Liang Dong

Suneel Gupta

Ann Hsu

Amy Ding

Ryan Vernon

Alex David Lester

Jon Mensing

Erik Eldridge

Yanli Li

Viren Baraiya

Hamid Mousavi

Victor Lum

Matthew Watson

Rajendra Gundluru

Dana Silver

Xin Wei

Vinkatram Jaltar

Shook-Fong Chin

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.

Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof

A system and method for conducting a parameter update event including one or more processors for transmitting first parameter settings to a program used by multiple users, such as a mobile device application at a plurality of mobile devices, receiving performance information indicating performance of the program after the first parameter setting, the performance information for each user being separately identifiable, and for each individual user of the plurality of users, determining a parameter setting update based at least in part on the performance information of the individual user and transmitting the parameter setting update to the program.

Personalized application configuration as a service

The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains a decarboxylase inhibitor wherein the one or more controlled release components are substantially free of the decarboxylase inhibitor.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising levodopa.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.

Growing community of inventors

Hayward, CA, United States of America

Liang Dong